Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy.
Proteinuria and enzymuria were measured in 27 patients with Cystic Fibrosis before and after tobramycin therapy. Prior to treatment, kidney function was normal in 23 patients. Four patients showed a pathological proteinuria and two haematuria. Renal biopsy in one patient showed segmental basement membrane alterations on electron microscopy; there were no immunoglobulin deposits. During intravenous therapy with tobramycin (10 mg/kg per day) and azlocillin (100 mg/kg per day) mean urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion rose six-fold and mean urinary alaninaminopeptidase excretion increased ten-fold. After cessation of therapy, enzymuria rapidly returned to pretreatment values in all 14 patients. Aerosol tobramycin therapy in four patients did not affect urinary excretion of NAG. It can be concluded that tobramycin did not cause persistent renal damage in our patients, whether given intravenously or as an aerosol.
D000118:Acetylglucosaminidase / Q000652:urine*; D000293:Adolescent; D000328:Adult; D000626:Aminopeptidases / Q000652:urine*; D001390:Azlocillin / Q000627:therapeutic use; D018826:CD13 Antigens; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*; D005260:Female; D006596:Hexosaminidases / Q000652:urine*; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D011507:Proteinuria / Q000209:etiology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology / Q000652:urine; D014031:Tobramycin / Q000627:therapeutic use*
D003404:Creatinine; D006596:Hexosaminidases; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D001390:Azlocillin; D014031:Tobramycin